Beware of buying online noninvasive continuous glucose monitoring devices: danger is just around the corner! DOI
Elena Gamarra,

G. Barchi,

Chiara Camponovo

et al.

Acta Diabetologica, Journal Year: 2023, Volume and Issue: 61(2), P. 253 - 255

Published: Sept. 30, 2023

Language: Английский

Appropriateness and acceptability of continuous glucose monitoring in people with type 1 diabetes at rural first-level hospitals in Malawi: a qualitative study DOI Creative Commons

Ada Thapa,

Stellar Chibvunde, Leah N. Schwartz

et al.

BMJ Open, Journal Year: 2024, Volume and Issue: 14(5), P. e075559 - e075559

Published: May 1, 2024

Objectives The purpose of this qualitative study is to describe the acceptability and appropriateness continuous glucose monitoring (CGM) in people living with type 1 diabetes (PLWT1D) at first-level (district) hospitals Malawi. Design We conducted semistructured interviews among PLWT1D healthcare providers participating study. Standardised interview guides elicited perspectives on CGM use for their providers, provider effectiveness Data were coded using Dedoose software analysed a thematic approach. Setting First-level Neno district, Participants part randomised controlled trial focused Pretrial post-trial participants usual care arms, one set was providers. Results Eleven recruited five who provided T1D included. Nine interviewed twice, two once. Of 11 T1D, six from arm arm. Key themes emerged regarding lower resource setting. four main (a) patient relationship, (b) stigma psychosocial support, (c) device usage (d) clinical management. Conclusions reported that appropriate acceptable setting, although need support it health education sessions highlighted. This research supports as component personalised treatment constraint settings. Trial registration number PACTR202102832069874; Post-results.

Language: Английский

Citations

3

Criteria for Personalised Choice of a Continuous Glucose Monitoring System: An Expert Opinion DOI Creative Commons
Sergio Di Molfetta, Antonio Rossi, Federico Boscari

et al.

Diabetes Therapy, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 30, 2024

Language: Английский

Citations

2

Linking MDA Levels and Blood Glucose in Streptozotocin-Induced Rat Diabetes: Implications for Diabetic Complications and Therapeutic Strategies DOI Open Access
Evelyn Angie, Ermi Girsang, Refi Ikhtiari

et al.

Jurnal Penelitian Pendidikan IPA, Journal Year: 2024, Volume and Issue: 10(6), P. 2898 - 2905

Published: June 20, 2024

Diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose levels resulting from insulin deficiency or resistance. Streptozotocin, potent diabetogenic agent, commonly employed to induce experimental diabetes selectively damaging pancreatic beta cells, in and hyperglycemia. Elevated Malondialdehyde (MDA) levels, indicative of oxidative stress lipid peroxidation, are closely linked diabetic complications. This study aimed investigate the association between MDA Streptozotocin-induced rat diabetes, shedding light on potential therapeutic strategies. Spectrophotometric analysis was utilized quantify tissues, providing insights into extent damage. The results revealed significant correlation glucose, highlighting role pathogenesis. These findings underscore importance targeting management prevent In conclusion, emphasizes relevance monitoring as biomarker for assessing conditions guiding interventions.

Language: Английский

Citations

1

Datafication of Care: Security and Privacy Issues with Health Technology for People with Diabetes DOI Creative Commons
Alessia Bertolazzi, Katarzyna Marzęda-Młynarska, Justyna Kięczkowska

et al.

Societies, Journal Year: 2024, Volume and Issue: 14(9), P. 163 - 163

Published: Aug. 29, 2024

Through the conceptual framework of datafication, dataism and dataveillance, this study investigates beliefs attitudes regarding datafication related privacy security concerns among individuals with Type 1 diabetes. Qualitative research was conducted through interviews fifty-two diabetes in Poland Italy. The findings reveal a dynamic interplay between self-discipline empowerment. majority interviewees emphasized benefits technologies for gaining better understanding their health condition more effective disease management. However, minority perceived negative effects including which leads to hyper-control disease, dataism, characterized by excessive reliance on dependency technology. Critical about fuelled rejection attitudes, leading some suspend or abandon use. Lastly, reflexivity issues appears be low, particularly older lower levels education socioeconomic status. This results poor underestimation potential risks associated privacy. increase factors that can facilitate hinder adoption technology people

Language: Английский

Citations

1

Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant‐level pooled analysis of three phase 3 LixiLan randomized controlled trials DOI Creative Commons
Martin Haluzı́k, Mohammed E. Al‐Sofiani, Alice Cheng

et al.

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 8, 2024

Abstract Aim To evaluate the efficacy of a fixed‐ratio combination insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D) using derived time‐in‐range (dTIR). Methods Participant‐level data from LixiLan‐L, LixiLan‐O and LixiLan‐G were pooled dTIR (70‐180 mg/dL), time‐above‐range (> 180 mg/dL) time‐below‐range (dTBR; < 70 calculated participant seven‐point self‐monitored blood glucose profiles. Results This analysis included 2420 participants receiving iGlarLixi ( n = 1093), iGlar 836), Lixi 234) or glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) 257). Numerically greater improvements least square (LS) means seen baseline to end treatment (EOT) (25.7%) versus (15.8%), (11.7%) GLP‐1 RA (16.2%). At EOT, mean (standard deviation) dTBR was 0.71% ± 3.4%, 0.61% 3.2%, 0.08% 1.0% 0.0% for iGlarLixi, iGlar, RA, respectively. In subgroup analysis, aged younger than 65 years 1690) older 713) showed numerically LS EOT RA. Conclusions achieved dTIR, low values, providing further evidence inform clinical outcomes use iGlarLixi.

Language: Английский

Citations

1

Genetic underpinnings of neonatal diabetes: a review of current research DOI Creative Commons
Mohammad Golshan-Tafti, Seyed Alireza Dastgheib, Reza Bahrami

et al.

Egyptian Journal of Medical Human Genetics, Journal Year: 2024, Volume and Issue: 25(1)

Published: Oct. 16, 2024

Abstract Neonatal diabetes mellitus (NDM) is a rare, insulin-dependent that manifests within the first month of life and requires insulin therapy for management. NDM categorized into two primary types: transient (TNDM), which typically resolves during infancy or early childhood, permanent (PNDM), necessitating lifelong treatment. TNDM has an incidence approximately 1 in 90,000 to 160,000 live births characterized by hyperglycemia usually 12 weeks but may relapse later adolescence adulthood. Congenital manifestations often include intrauterine growth restriction (IUGR), macroglossia, umbilical hernia, with its etiology linked epigenetic alterations on chromosome 6q24 affect transcription factor PLAGL1. In contrast, PNDM occurs ranging from 108,999 1,029,999 presents persistent requiring therapy. It primarily associated mutations over 49 genes, particularly KCNJ11 ABCC8, disrupt ATP-sensitive potassium channels, while some cases involve gene β-cell function. Treatment mainly consists therapy, although patients transition oral sulfonylureas. Long-term follow-up multidisciplinary pediatric team crucial, as individuals experience recurrent neurological neuropsychological issues. Insulin effective approach managing NDM, meticulous monitoring blood glucose levels reduce risk long-term complications. Genetic testing essential diagnosing both types informing treatment strategies, including potential use sulfonylureas PNDM. Ongoing research genetic mechanisms management approaches vital enhancing clinical outcomes complications affected individuals.

Language: Английский

Citations

1

Enhancing Patient-Centered Care Through Firsthand Experience With Continuous Glucose Monitoring in Rural Wyoming DOI Open Access

Drew Mahoney,

Lavinia Salama

The Annals of Family Medicine, Journal Year: 2024, Volume and Issue: 22(1), P. 69 - 69

Published: Jan. 1, 2024

At the University of Wyoming Family Medicine Residency (UWFMR), we recognized pressing need to deepen our understanding daily challenges faced by patients with diabetes. To facilitate better learning and stronger patient relationships, embarked on a unique initiative—to gain

Language: Английский

Citations

0

A method for evaluating the risks of glucose dysregulation in daily life by continuous measurement of glucose excursions under reduced glycemic load: a pilot study DOI Creative Commons

Yoshitada Katagiri,

Hiromi Ozaku,

Katsuhiko Kondo

et al.

Frontiers in Sensors, Journal Year: 2024, Volume and Issue: 5

Published: May 7, 2024

Introduction: Continuous glucose monitoring is essential for the management of patients with metabolic syndromes in their daily lives. However, how risks are accessed using time-series excursion data healthy individuals remains unclear. Methods: Thus, this study aimed to present a method evaluating dysregulation by analyzing responses under reduced glycemic load phytochemical alpha-glucosidase inhibitor. A 14-day pilot trial adult participants was conducted demonstrate validity method. Results and Discussion: The results showed that ultradian spike packets lower heights dominantly appeared load, replacing postprandial single-lobe spikes higher heights. Furthermore, frequency dominance contributed reduction overall mean excursions during test period load. Based on time-delay model, it indicated recovers regular glucose–insulin coupling accompanying oscillations, thereby contributing maintenance homeostasis. findings indicate ratio between pulsatile could be marker regulation/dysregulation adults.

Language: Английский

Citations

0

Exploring Real-World Adherence and Cost Implications of Continuous Glucose Monitoring in Patients with Diabetes: Impact of Device Sourcing (Preprint) DOI Creative Commons
Jason C. Allaire,

Consuela Dennis,

A Masturzo

et al.

JMIR Diabetes, Journal Year: 2024, Volume and Issue: 9, P. e58832 - e58832

Published: May 25, 2024

Insurance benefit design influences whether individuals with diabetes who require a continuous glucose monitor (CGM) to provide real-time feedback on their blood levels can obtain the CGM device from either pharmacy or durable medical equipment supplier. The impact of acquisition channel adherence and health care costs has not been systematically evaluated.

Language: Английский

Citations

0

Adherence to Self-Monitoring of Blood Glucose and Its Related Factors Among Type 2 Diabetic Patients Attending Al-Ahsa Primary Health Care Centers in Saudi Arabia DOI Open Access

Afnan AlRasheed,

Hajer Hashim,

Hassan Alrofaie

et al.

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: July 27, 2024

Background: Self-monitoring of blood glucose (SMBG) is a crucial component diabetes management, but adherence remains suboptimal. This study aimed to evaluate SMBG among type 2 diabetic patients in Al-Ahsa, Saudi Arabia. Methods: A cross-sectional was conducted 398 attending primary healthcare centers. Data were collected through face-to-face or virtual interviews and electronic health records. Adherence levels categorized as low, moderate, high. Results: The majority participants exhibited moderate (58.5%), while 27.1% had low adherence, 14.3% highly adherent. use oral hypoglycemic medications insulin injections associated with higher (p<0.001). Comorbidities, physical exercise, diet, frequency medical visits, attendance at education sessions did not significantly influence adherence. Conclusions: Suboptimal observed Al-Ahsa. Targeted interventions addressing individual barriers integrating technology may improve management.

Language: Английский

Citations

0